INmune Bio: An Opportunity In The Freefall (Rating Upgrade)

picturegarden/DigitalVision via Getty Images Topline Summary and Update INmune Bio (NASDAQ:INMB) is a company focused on developing drugs in two different disease areas: neurology and cancer medicine. I've previously covered this company in two articles, and I was a cautious optimist in my latest outing, with main reservations related to their cash burn rate and the challenges of developing drugs for Alzheimer disease, which is their most advanced focus. This article is an update providing a picture of  ...